Although a variety of targeted molecular inhibitors can exert potential anti-tumor effects through the PI3K/AKT/mTOR pathway, to date, the clinical efficacy of these inhibitors as a monotherapy has shown meager response rates. Here, PIK3CA is linked to neoplasm.